Pacira Earnings Call Highlights Margin Gains And Growth

Pacira ((PCRX)) has held its Q4 earnings call. Read on for the main highlights of the call.

Pacira’s latest earnings call struck a cautiously upbeat tone, with management leaning on record gross margins, accelerating EXPAREL volumes, and a fortified intellectual‑property moat to frame a long growth runway. Rising R&D and SG&A, discounting pressure, and near‑term margin noise were acknowledged, but executives argued that strategic investment and partnerships should outweigh these headwinds over time.

Record Revenue and Margin Ambitions

Pacira closed fiscal 2025 with total revenue of $726 million and a fourth‑quarter consolidated non‑GAAP gross margin of 80%, edging up from 79% a year ago and marking the highest margin in the company’s history. Management reiterated a long‑term target to expand non‑GAAP gross margin by about five percentage points versus 2024’s 76% level by 2030, signaling confidence in structural profitability gains.

EXPAREL Volume Rebound Supports Top Line

EXPAREL returned to healthy growth in the fourth quarter, with sales of $155.8 million versus $147.7 million in the prior year, a roughly 5.5% revenue increase. Underpinning that result, management highlighted approximately 7% year‑over‑year volume growth in Q4, evidence that broader commercial efforts are translating into more procedures using the non‑opioid pain drug.

Broader Payer Coverage and Market Access Wins

Market access has become a central growth driver, as Pacira ended 2025 with about 102 million lives covered for EXPAREL outside the surgical bundle and indicated this figure has already climbed to roughly 110 million in early 2026. Key wins with major payers such as Aetna, Cigna, TRICARE, and Humana, along with Medicare ASP+6% outpatient reimbursement, are making it easier for hospitals and ambulatory centers to adopt the product.

Strategic Partnerships and International Expansion

Management emphasized a more global footprint, spotlighting a partnership with LG Chem to commercialize EXPAREL in South Korea and Thailand, with regulatory filings expected in 2026 and revenue contributions anticipated from 2027. In the U.S., a fully trained J&J MedTech sales organization is now working to expand ZILRETTA’s reach, a shift Pacira expects will provide the commercial muscle required for that franchise to reaccelerate.

IP Position and Litigation Resolution Extend Runway

Pacira’s intellectual‑property story has turned into a strategic asset, with the company now holding 21 patents across two families compared with just one patent at the time of its initial Paragraph IV challenge. A volume‑limited settlement with Fresenius provides visibility for EXPAREL through 2039, reducing the near‑term risk of generic erosion and supporting management’s long‑term planning.

Pipeline Progress and Upcoming Data Events

The company framed 2026 as a data‑rich year for its pipeline, led by the ASCEND program for PCRX‑201, where 52‑week data from Part A in 49 patients are expected by year‑end and Part B is slated to enroll around 90 patients starting mid‑year. Additional catalysts include interim analyses and top‑line readouts planned in 2026 for ZILRETTA in shoulder osteoarthritis and ioverao in spasticity, which could broaden Pacira’s non‑opioid pain and musculoskeletal portfolio.

Cash Strength and Ongoing Share Repurchases

Pacira exited the fourth quarter with $238 million in cash and investments, giving the balance sheet room to fund R&D and business development while returning capital. The company has repurchased $150 million of stock year‑to‑date, including $50 million in Q4, retiring roughly 2 million shares and bringing the count to about 41 million, with another $150 million still authorized for buybacks.

Manufacturing Gains Support Margin Expansion

Operationally, the new 200‑liter EXPAREL facilities are delivering better‑than‑expected yields, driving lower per‑unit costs and supporting the record gross margins reported. Management is fine‑tuning production levels to align with inventory targets and expects ongoing continuous‑improvement programs in manufacturing to underpin steady margin increases over time.

Higher R&D and SG&A Weigh on Near-Term Earnings

The earnings profile is feeling the impact of stepped‑up investment, with fourth‑quarter non‑GAAP R&D spending rising to $34.4 million from $22 million, reflecting a $5 million upfront in‑license payment and advancement of clinical programs. Non‑GAAP SG&A climbed to $91.9 million from $70.6 million, driven in part by business development due diligence and litigation expenses that management characterized as elevated in the near term.

Pricing, Mix, and GPO Discounts Temper Revenue

While EXPAREL volumes grew about 7% in the quarter, the full benefit did not drop to the top line because of an unfavorable buy mix and increased discounting tied to a third group purchasing organization going live. These dynamics partially offset revenue growth and underscore how contracting strategies and channel mix can influence realized pricing even in a rising‑volume environment.

Flat ZILRETTA Sales Highlight Execution Needs

ZILRETTA, Pacira’s extended‑release steroid for knee osteoarthritis pain, delivered fourth‑quarter sales of $33 million, essentially flat versus the prior year. Management tied the sluggish trend to earlier reorganization efforts and reiterated that renewed growth will depend on building momentum through the partner‑led J&J MedTech commercialization model.

Margin Timing and Inventory Effects Create Near-Term Noise

Investors were cautioned about near‑term margin volatility, with first‑quarter 2026 EXPAREL contribution expected to be roughly one percentage point lower due to winter storms that disrupted procedures. In addition, fourth‑quarter margins are projected to lag the full‑year range as Pacira sells through higher‑cost inventory and absorbs shutdown‑related expenses, creating a back‑weighted profitability profile.

Pipeline Risk and Statistical Power Limit De-Risking

Management was candid that some pipeline programs remain in the earlier, higher‑risk phase of development, noting that ASCEND Part A for PCRX‑201 is primarily a safety study and not statistically powered to show efficacy. As a result, any efficacy signals from this cohort will be exploratory, and more robust de‑risking will likely have to wait for Part B and potential registrational‑scale data.

Stepped-Up Spend and One-Offs Pressure Profitability

Beyond the quarter, Pacira signaled that elevated R&D and SG&A will continue to weigh on near‑term earnings, with 2026 non‑GAAP R&D guided to $105 million to $115 million. The company also pointed to unanticipated business development and litigation costs embedded in SG&A, suggesting that investors should brace for a period of heavier spending before operating leverage kicks back in.

Guidance and Outlook

For 2026, Pacira guided to total revenue of $745 million to $770 million, including EXPAREL sales of $600 million to $620 million plus about $7 million from a veterinary license, while assuming ZILRETTA and ioverao remain roughly flat versus 2025. Non‑GAAP gross margin is forecast between 77% and 79%, with Q1 slightly softer due to storms and Q4 below the range on inventory effects, alongside non‑GAAP R&D of $105 million to $115 million and SG&A of $320 million to $340 million.

Pacira’s call presented a company leaning into its strengths—EXPAREL’s renewed volume growth, expanding access, stronger IP, and an increasingly global and diversified pain‑management portfolio—while accepting higher spend and some pricing friction as the cost of future growth. For investors, the story now hinges on execution: turning margin initiatives, payer wins, and a maturing pipeline into durable earnings power over the back half of the decade.